June 22, 2016
Voyager Therapeutics, Inc. VYGR 2.74% disclosed interim surgical results from an ongoing Phase 1b study of VY-AADC01 in patients with advanced Parkinson's disease as a poster presentation at the 20th International Congress of Parkinson's Disease and Movement Disorders (ICPDMD) in Berlin, Germany. The company claimed that the results demonstrated the continued safety in all 10 patients.
Voyager Therapeutics' VP of clinical development, Bernard Ravina, commented, "Importantly, the use of real-time, intra-operative MRI-guided delivery allowed the surgical teams to visualize the delivery of VY-AADC01, administer higher infusion volumes, and achieve greater coverage of the putamen, the brain region that we are targeting with our gene therapy program. "
He continued, "Increased infusion volumes of VY-AADC01 in Cohort 2 resulted in a higher average coverage of the overall putamen of 34% compared to 21% in Cohort 1. This is substantially greater coverage of the putamen than has been achieved in previous gene therapy trials using a similar vector, and represents an important threshold based on preclinical studies."
The VP concluded, "Obtaining sufficient coverage of the putamen with VY-AADC01 is a key step towards potentially improving patients' response to levodopa, the standard of care treatment for Parkinson's disease, and will allow us to begin to more fully assess the impact of VY-AADC01 on patients' motor symptoms from the top-line results of this study expected later this year."
On Tuesday, the stock lost 9.25 percent.
Read more: http://www.benzinga.com/general/biotech/16/06/8139226/voyager-therapeutics-reveals-interim-phase-1b-surgical-results-for-vy-
#http://health.einnews.com/article/332154699/aEFBZBLD4zGmGcFD
No comments:
Post a Comment